Trials 21
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials · 1 met primary | ||||||
| Phase 1 | NCT04550234 | Apr → Jul 2021 | chronic kidney disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04532918 | Sep → Nov 2020 | chronic kidney disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04256629 | Mar → Aug 2020 | — | AstraZeneca | Completed | Met primary |
| Phase 1 | NCT04024501 | Jul → Sep 2019 | chronic kidney disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03836599 | Jan → Apr 2019 | chronic kidney disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02608710 | Nov → Dec 2015 | gout | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02448368 | May → Jun 2015 | — | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02279641 | Nov 2014 → Apr 2015 | gout | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02336594 | Nov 2014 → Jan 2015 | gout | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02219516 | Aug 2014 → Oct 2015 | gout | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01910506 | Aug → Sep 2013 | — | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01872832 | Jun → Sep 2013 | gout | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01883167 | Jun → Sep 2013 | — | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02317861 | Dec 2014 → Jun 2015 | gout | AstraZeneca | Completed | No outcome recorded |
| Phase 27 trials · 2 met primary · 2 missed | ||||||
| Phase 2 | NCT04327024 | May 2020 → Apr 2022 | diastolic heart failure | AstraZeneca | Completed | Missed primary |
| Phase 2 | NCT03990363 | Jul 2019 → Nov 2021 | chronic kidney disease | AstraZeneca | Completed | Missed primary |
| Phase 2 | NCT03118739 | May 2017 → Aug 2018 | proteinuria, type 2 diabetes mellitus | AstraZeneca | Completed | Met primary |
| Phase 2 | NCT02498652 | Jul → Nov 2015 | gout | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02246673 | Oct 2014 → Jul 2015 | gout | Ardea Biosciences, Inc. | Completed | Mixed |
| Phase 2 | NCT02078219 | Jan 2014 → Mar 2015 | gout | AstraZeneca | Completed | Met primary |
| Phase 2 | NCT01927198 | Aug 2013 → May 2014 | gout | Ardea Biosciences, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03316131 Background | Oct 2017 → Jul 2018 | — | AstraZeneca | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-10-30 | AstraZeneca | Results AstraZeneca to present pivotal roxadustat Phase III data at the American Society of Nephrology Kidney Week 2019 astrazeneca.com ↗
CITRINE: Verinurad Plus Febuxostat Rapidly Reduces Albuminuria in Type 2 Diabetes Independent of Pre-existing Kidney Disease |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-10-30 | AstraZeneca | AstraZeneca to present pivotal roxadustat Phase III data at the American Society of Nephrology Kidney Week 2019 astrazeneca.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Verinurad | “Verinurad (RDEA3170) is a high affinity, selective uric acid transporter (URAT1) inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia.” PMID 29531784 ↗ Feb 201812“Verinurad (RDEA3170) is a high-affinity inhibitor of the URAT1 transporter in clinical development for treating gout and asymptomatic hyperuricaemia.” PMID 29868853 ↗ Sep 2018 “Verinurad (RDEA3170) is a high-affinity, selective URAT1 transporter inhibitor in development for treating gout and asymptomatic hyperuricemia.” PMID 29949102 ↗ Aug 2018 “Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treating gout and asymptomatic hyperuricaemia.” PMID 29657831 ↗ Apr 2018 “Randomized patients will receive orally once daily fixed dose of verinurad in 2 treatment sequences AB or BA for 7 consecutive days.” NCT03316131 ↗ |
| Known as | RDEA3170 | “Verinurad (RDEA3170) is a high affinity, selective uric acid transporter (URAT1) inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia.” PMID 29531784 ↗ Feb 201813“Verinurad (RDEA3170) is a high-affinity inhibitor of the URAT1 transporter in clinical development for treating gout and asymptomatic hyperuricaemia.” PMID 29868853 ↗ Sep 2018 “Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treating gout and asymptomatic hyperuricaemia.” PMID 29657831 ↗ Apr 2018 “Verinurad (RDEA3170) is a novel URAT1 inhibitor in Phase 2 development for chronic kidney disease and heart failure.” NCT03990363 ↗ |
| Action | Inhibit | “Solute carrier family 22 member 12 inhibitor” CHEMBL3707347 ↗1“the investigational URAT1 inhibitor RDEA3170” NCT01883167 ↗ |
| Modality | Small molecule | — CHEMBL3707347 ↗ |
| Route | Oral | “RDEA3170 oral solution” NCT01910506 ↗ |
| Target | SLC22A12 | “Solute carrier family 22 member 12 inhibitor” CHEMBL3707347 ↗ |